BioMimetic Pharmaceuticals
Dr. Samuel Lynch, Chairman & CEO

BioMimetic Therapeutics, Inc. is an emerging leader in the development and commercialization of drug-device combination products for the repair of orthopedic injuries to bone, cartilage, ligaments and tendons. BioMimetic’s suite of products and product candidates combine recombinant protein therapeutics with tissue specific scaffolds, actively stimulating tissue healing and regeneration. BioMimetic believes its biologically-enhanced orthopedic therapies can improve the treatment options and quality of life for millions of patients suffering injuries or deterioration of the bones, cartilage (joints), ligaments and tendons.